Current therapeutic ranges showed low sensitivity, while lower proposed ranges improved sensitivity considerably.<h4>Conclusions</h4>Current anti-TNF therapeutic ranges have limited ability to identify responders in real-world RA. This evidence concerns the gene TNF and rheumatoid arthritis.